Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jun 03, 2021 10:10am
115 Views
Post# 33318293

RE:RE:RE:Great

RE:RE:RE:Great This is what LSA does, would they approach retail investors? Will we get that report soon after the webinar?

"LifeSci Advisors’ Approach

 
LifeSci Advisors employs a “client as partner” approach to our company relationships. From the beginning of each client relationship, we immerse ourselves in the subject matter and work closely with the client to develop an unparalleled and thorough understanding of the value of their business, the opportunities they’re addressing and their unique value proposition. With this insight, LifeSci Advisors provides each client with thoughtful and strategic recommendations related to corporate communications, investor targeting and investor outreach. These recommendations are specifically tailored to each client’s unique needs and designed to help them achieve their investor relations goals. We strive to effectively communicate each client’s investment thesis, which builds important momentum for the company’s investment story."
<< Previous
Bullboard Posts
Next >>